Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00826033 |
Recruitment Status
:
Completed
First Posted
: January 21, 2009
Last Update Posted
: January 21, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for positron emission tomography (PET). The investigators evaluated the value of 18F-FMT PET for the assessment of therapy response in patients with lung cancer as compared with that of 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) PET.
The patients with lung cancer underwent PET studies with 18F-FDG and 18F-FMT before and after radio-/chemotherapy. The investigators used the ratio of the SUVmax of the mediastinal (N2) lymph node to the SUVmax of the primary tumor (N/P ratio ). All patients were divided into two groups of N/P ratio<1 and N/P ratio≥1, and the survival time was estimated by Kaplan-Meier method.
Condition or disease |
---|
Non-Small Cell Lung Cancer |
Study Type : | Observational |
Time Perspective: | Prospective |
Official Title: | Fluorine-18-α-Methyltyrosine Positron Emission Tomography to Measure Therapy |

Group/Cohort |
---|
Therapy monitoring |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- primary lung cancer All patients received first-line chemotherapy
Exclusion Criteria:
- Patients with diabetus mellitus

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00826033
Japan | |
Gunma University Graduate School of Medicine | |
Gunma, Japan, 371-8511 |
ClinicalTrials.gov Identifier: | NCT00826033 History of Changes |
Other Study ID Numbers: |
Mol Imaing 1 |
First Posted: | January 21, 2009 Key Record Dates |
Last Update Posted: | January 21, 2009 |
Last Verified: | January 2009 |
Keywords provided by Gunma University:
Fluorine-18-α-methyltyrosine Positron emission tomography Lung cancer chemotherapy monitoring |
Additional relevant MeSH terms:
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic |
Bronchial Neoplasms Fluorides alpha-Methyltyrosine Cariostatic Agents Protective Agents Physiological Effects of Drugs Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |